

ERRATUM

Autism spectrum disorders

Sarah Nightingale

Nature Reviews Drug Discovery 11, 745–746 (2012)

There were some inaccuracies in the description of the compound STX-209 (arbaclofen; Seaside Therapeutics) in the text and table of the article. The compound is currently under Phase IIb clinical investigation for the treatment of the core symptoms of autism spectrum disorders, and it is formulated as an oral rapid disintegrating tablet. This information has been updated in the online version of the article.